Australian nasal spray claims to reduce Covid-19 growth by 96%
India TodayA nasal spray being developed to improve the human immune system to fight common cold and flu can significantly reduce the growth of the coronavirus, claimed the Australian biotech company Ena Respiratory after it conducted a study on animals. A study on ferrets showed the product dubbed INNA-051, which could be used complementary to vaccines, lowered the levels of the virus that causes Covid-19 by up to 96 per cent, the company said. Ena Respiratory said it would be ready to test INNA-051 in human trials in less than four months, subject to successful toxicity studies and regulatory approval. Investors include venture capital firm Brandon Capital Ltd, the Australian federal government, pension funds and biotech giant CSL Ltd. Several companies across the world are in the pursuit of developing a coronavirus vaccine.